Anti-CD20 Immunocytokine, IgG (DI-Leu16)-IL2 (ACFP-SH134)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD20 as well as the biological activity of IL2. In-vitro studies of DI-Leu16-IL2 have demonstrated CD20 targeting, IL2 bioactivities, and antibody-dependent cell-mediated cytotoxicity (ADCC) functions. In a SCID mouse model, DI-Leu16-IL2 showed superior anti-lymphoma effects over rituximab or rituximab combined with systemic IL2. This immunocytokine was designed for treating Non-Hodgkin Lymphoma.
Specifications
- Target
- CD20
- Molecule Class
- L Kappa; IgG1-IL2
- Species Reactivity
- Human
- Host
- Chimeric (Human-Mouse)
- Expression Host
- CHO
- Clone
- DI-Leu16
- Related Disease
- Non-Hodgkin Lymphoma
- Cytokines 1
- IL2
- Cytokines 1 Description
- Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- MS4A1; membrane-spanning 4-domains; subfamily A; member 1; B1; S7; Bp35; CD20
- Entrez Gene ID
- 931
- UniProt ID
- A0A024R507
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: